Recent Updates
Recently added Catalysts
VNRX Positive Sentiment

Nu.Q® Discover – Markets & Markets Next-Gen Immuno-Oncology Conference

Friday, March 8, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Volition attended the Markets and Markets Next-Gen Immuno-Oncology Conference in London in March 2024, where they discussed their Nu.Q® Discover program. The event allowed the Volition team to connect with industry professionals and share insights on advancements in immuno-oncology. The conference highlighted the potential of their cancer test and its prognostic value.
Price reaction · baseline $19.8 (2024-03-07 close) · hit pre-market · 1 other VNRX headline(s) in the window, move may be shared
day 0 close · peak
+3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Volition showcased its Nu.Q® Discover program at a prominent conference.
  • The conference provided valuable insights into next-gen immuno-oncology.
  • Engagement with industry professionals could enhance future collaborations.

Full Press Release Details

Volition attended the Markets and Markets Next-Gen Immuno-Oncology Conference in London, March 2024. Hear from members of our Volition team about how the conference went and the scope of our Nu.Q ® Discover programme.

Related Articles

• Press Releases Data Showing the Prognostic Value of its Nu.Q® Cancer Test
• Poster & Publications Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

Data Showing the Prognostic Value of its Nu.Q® Cancer Test

Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

• Share
• Tweet
• Share on Facebook
• Share

Subscribe for Volition product updates .

Or, click here for Investor Updates and press releases .

" * " indicates required fields

Frequently Asked Questions

What is the Nu.Q® Discover program?

The Nu.Q® Discover program focuses on advancements in cancer testing and immuno-oncology.

When did Volition attend the conference?

Volition attended the Markets and Markets Next-Gen Immuno-Oncology Conference in March 2024.

Where was the conference held?

The conference took place in London.

What was discussed at the conference?

The conference highlighted the Nu.Q® Discover program and its prognostic value in cancer testing.

ShareAdd on Google
Tags: VNRX Viatris Investor Conferences Healthcare Nu.Q immuno-oncology cancer test London conference
Last updated: Mar 8, 2024

Biotech snapshot

Cash runway
$3M liquidity · $2M/mo burn
~1 mo
High dilution risk